System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Melinda Gooderham is an expert in Dermatology at Probity Medical Research (Canada). As of October 2026, ScienceLeadR ranks Melinda Gooderham in the top 1% of experts worldwide for Dermatitis, Psoriasis and Skin Diseases, Eczematous. Melinda Gooderham has authored 595 publications, the most recent in 2026, and is an investigator in 46 clinical trials, 6 of them ongoing. SLR score: 2,739 (community average: 125). How the SLR is computed.

LeadR Profile

Melinda Gooderham Probity Medical Research Canada
2 739 ScienceLeadR Reputation 2739

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Immunology - Public Health - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2014 - 2026
Source: PubMed

SKiN Health

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 595

Citations

Citations: 16 890 1st author: 77 Last author: 91 Unique author: 4

Main journals

J Am Acad Dermatol 100
J Cutan Med Surg 58
Br J Dermatol 55
Dermatol Ther (Heidelb) 51
SKIN The Journal of Cutaneous Medicine 51

Best Journals

N Engl J Med 10
Lancet 3
JAMA 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
PMID 42584887 — quality of life, achievement, safety, alopecia areata, skin diseases, drug-related side effects and adverse reactions, adolescent, therapeutics, alopecia		JAMA Dermatol20261
Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
PMID 42907530 — hidradenitis suppurativa, hidradenitis		Nat Med Top journal20260
Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.
PMID 42844558 — safety, dermatitis, dermatitis, atopic		Dermatol Ther (Heidelb)20260
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
PMID 42789172 — safety, alopecia areata, therapeutics, alopecia		Am J Clin Dermatol20260
Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study.
PMID 42728527 — quality of life, safety, dermatitis, therapeutics, dermatitis, atopic		Dermatol Ther (Heidelb)20260

Clinical Studies 46

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 24
Phase 2 16
N/A 4
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 38
Recruiting 4
Active not recruiting 3
No longer available 1

By type:

Interventional 42
Observational 3
Expanded Access 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 1
multicentricup10 42

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263 — abscess, skin, safety, pharmaceutical preparations, hidradenitis suppurativa, drug therapy, hidradenitis, therapeutics		Phase 2Recruiting2026
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283 — skin, safety, pharmaceutical preparations, vitiligo, drug therapy, capsules, immune system, therapeutics		Phase 2Recruiting2025
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate to Severe Atopic Dermatitis
NCT06136741 — injections, gtp-binding proteins, safety, dermatitis, pharmaceutical preparations, solutions, rhoa gtp-binding protein, therapeutics, guanosine triphosphate, dermatitis, atopic		Phase 2Active not recruiting2023
A Study of JNJ 77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp Genital and or Palms of the Hands and the Soles of the Feet)
NCT06095102 — safety, foot, therapeutics, psoriasis		Phase 3Active not recruiting2023
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240 — safety, alopecia areata, pharmaceutical preparations, tablets, adolescent, therapeutics, alopecia		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS